检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王雪 马岩松 韦薇 何伍 WANG Xue;MA Yan-song;WEI Wei;HE Wu(Center for Drug Evaluation,National Medical Products Administration,Beijing 100076,China;Center for Food and Drug Inspection,National Medical Products Administration,Beijing 100076,China)
机构地区:[1]国家药品监督管理局药品审评中心,北京100076 [2]国家药品监督管理局食品药品审核查验中心,北京100076
出 处:《中国新药杂志》2023年第24期2447-2451,共5页Chinese Journal of New Drugs
摘 要:自体嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)治疗产品在肿瘤治疗尤其是血液系统肿瘤治疗方面为患者带来了显著的生存获益,但自体CAR-T类治疗产品常见的生产模式流程复杂、周期较长,造成该类产品的产能在一定程度上限制了其临床应用。本文结合当前研究进展,在针对自体CAR-T细胞产品常见生产模式分析的基础上,提出自体CAR-T类治疗产品产能确认研究和产能变更研究内容与评价考虑,以期能促进此类产品的研发和临床应用。Autologous chimeric antigen receptor T cell(CAR-T)cell therapy products have brought significant survival benefits to tumor patients,especially in the treatment of hematologic tumors.However,the common production mode of autologous CAR-T therapy products is complicated and has a long cycle.As a result,the production capacity of this kind of products has limited their clinical application to a certain extent.In this paper,based on the analysis of the common production mode of autologous CAR-T cell products,the content and evaluation of the capacity confirmation study and capacity change study of autologous CAR-T therapeutic products are proposed in combination with the current research progress,hoping to effectively promote the development and clinical application of such products.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117